A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer

Condition:   Chemotherapy-induced Nausea and Vomiting Interventions:   Drug: fosnetupitant/ palonosetron;   Drug: netupitant/palonosetron;   Drug: dexamethasone Sponsors:   Helsinn Healthcare SA;   George Clinical Pty Ltd;   PSI CRO AG Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials